A study found that 30% SSA effectively reduces papules, pustules, and redness in papulopustular rosacea while improving skin hydration. The treatment showed significant benefits compared to a placebo, making it a promising option for rosacea management.

A recent study published in the Journal of Cosmetic Dermatology highlighted the effectiveness of 30% supramolecular salicylic acid (SSA) in managing papulopustular rosacea, a chronic skin condition that affects millions worldwide.  

The study involved 34 patients randomly assigned to an experimental group treated with 30% SSA or a control group receiving a placebo. Researchers assessed improvements in skin lesions, erythema, and skin barrier function through various clinical measures, including lesion reduction rates, investigator severity assessment (ISA) scores, and VISIA redness scores.  

Findings revealed a 68.75% effectiveness rate in the SSA group, significantly reducing papules and pustules (p < 0.01). The experimental group also demonstrated lower ISA scores (1.75 ± 0.68 vs. 2.40 ± 0.83, p < 0.05) and a 25.1% improvement in redness scores (p < 0.01). Skin hydration improved significantly, while sebum levels decreased on the cheeks and forehead (p < 0.05). However, no notable differences were observed in trans-epidermal water loss (TEWL) or skin pH.  

The study suggested that 30% SSA is a safe and effective alternative for rosacea management, offering promising results in reducing inflammation and improving skin hydration.

(Source:https://onlinelibrary.wiley.com/doi/full/10.1111/jocd.70046 )